Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Chimeric fusion proteins--Pseudomonas exotoxin-based.

R J Kreitman1

  • 1National Cancer Institute, NIH, Clinical Immunotherapy Section, Laboratory of Molecular Biology, Division of Cancer Biology, 9000 Rockville Pike, Building 37, Room 4B-27, Bethesda, MD 20892-4255, USA. kreitmar@mail.nih.gov

Current Opinion in Investigational Drugs (London, England : 2000)
|November 23, 2001
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Dabrafenib plus trametinib in patients with BRAF V600E-mutant anaplastic thyroid cancer: updated analysis from the phase II ROAR basket study.

Annals of oncology : official journal of the European Society for Medical Oncology·2022
Same author

Essential role for Bim in mediating the apoptotic and antitumor activities of immunotoxins.

Oncogene·2017
Same author

12 making fusion toxins to target leukemia and lymphoma.

Methods in molecular medicine·2011
Same author

Elevation of soluble CD307 (IRTA2/FcRH5) protein in the blood and expression on malignant cells of patients with multiple myeloma, chronic lymphocytic leukemia, and mantle cell lymphoma.

Leukemia·2006
Same author

SV40 Pseudovirion gene delivery of a toxin to treat human adenocarcinomas in mice.

Cancer gene therapy·2006
Same author

IBC's international Conference on Novel Therapeutic Proteins for Oncology (drug discovery and development).

Expert opinion on investigational drugs·2005

Recombinant fusion toxins offer advantages over traditional immunotoxins, including targeted delivery and improved safety profiles. This review focuses on agents using truncated Pseudomonas exotoxin in development.

Area of Science:

  • Biotechnology
  • Molecular Biology
  • Oncology

Background:

  • Recombinant fusion toxins present advantages over chemical conjugates, such as defined junctions and scalable bacterial production.
  • They offer potential for reduced vascular leak syndrome (VLS) due to shorter plasma half-lives.
  • Genetic engineering allows for enhanced potency and reduced non-specific toxicity of these toxins.

Purpose of the Study:

  • To review the development and potential of recombinant fusion toxins, particularly those employing truncated Pseudomonas exotoxin.
  • To highlight the advantages of recombinant approaches in immunotoxin design.

Main Methods:

  • Focus on agents containing truncated Pseudomonas exotoxin.
  • Discussion of growth factor fusion toxins and recombinant immunotoxins.

Related Experiment Videos

  • Review of preclinical and clinical development stages.

    • Main Results:

    • Recombinant fusion toxins utilize ligands for selective tumor cell binding and toxin-mediated cell killing.
    • Pseudomonas exotoxin and diphtheria toxin are common bacterial toxins used in these constructs.
    • Several agents with truncated Pseudomonas exotoxin are in active development.

    Conclusions:

    • Recombinant fusion toxins represent a promising advancement in targeted cancer therapy.
    • Truncated Pseudomonas exotoxin-based agents show significant potential in preclinical and clinical settings.